Drug intelligence / Profile preview

recombinant hepatitis B vaccine Bio Farma

Development stage
Phase 4
Lead developer
Bio Farma
Modality
Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
Administration
Intramuscular
01

Overview

The recombinant hepatitis B vaccine developed by PT Bio Farma is a biologic vaccine designed for active immunization against hepatitis B virus infection. The active ingredient is inactivated hepatitis B surface antigen (HBsAg) produced in yeast cells (*Hansenula polymorpha*) using recombinant DNA technology. PT Bio Farma has been producing this vaccine since 2000 to meet Indonesia's national immunization program requirements. The vaccine is presented as a whitish liquid and works by stimulating the immune system to produce antibodies against HBsAg. Clinical trials have demonstrated that the vaccine is immunogenic, well-tolerated, and safe, with studies evaluating different bulk antigen sources including those from the Serum Institute of India and Janssen Vaccine Corp.

Brand names
Hepatitis B Bio Farma
Other names
Recombinant Hepatitis B vaccineHepatitis B vaccine recombinant
02

Targets

B2GP1 (Beta-2-glycoprotein I)HBsAg (Hepatitis B surface antigen)

Beyond the preview

Go deeper on recombinant hepatitis B vaccine Bio Farma.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on recombinant hepatitis B vaccine Bio Farma.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call